• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by 111 Inc.

    7/19/24 6:08:35 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $YI alert in real time by email
    6-K 1 dp214579_6k.htm FORM 6-K

     

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN -PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2024

     

     

     

    Commission File Number: 001-38639

     

     

     

    111, Inc.

    3-4/F, No.295 ZuChongZhi Road,

    Pudong New Area

    Shanghai, 201203

    The People’s Republic of China

    (Address of principal executive offices)

     

     

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.    Form 20-F  ☒      Form 40-F  ☐

     

     

     

     

     

     

    Incorporation by Reference

     

    This report on Form 6-K shall be deemed to be incorporated by reference in the registration statements of 111, Inc. (the “Company”) on Form S-8 (No. 333-229313), to the extent not superseded by documents or reports subsequently filed.

     

    The Company intends to use this Form 6-K and the accompanying exhibit to satisfy its reporting obligations under Item 16F(a) of its Form 20-F for the fiscal year ending December 31, 2024 to the extent provided in and permitted by Paragraph 2 of the Instructions to Item 16F of Form 20-F and plans to incorporate Exhibit 16.1 by reference into such Form 20-F to the extent necessary to satisfy such reporting obligations.

     

    Change in Registrant’s Independent Registered Public Accounting Firm

     

    Effective as of July 19, 2024, the Company engaged Grant Thornton Zhitong Certified Public Accountants LLP (“Grant Thornton”) as the Company’s independent registered public accounting firm, and dismissed Deloitte Touche Tohmatsu Certified Public Accountants LLP (“Deloitte”). The change in the Company’s independent registered public accounting firm has been duly approved by the Company’s board of directors and audit committee. The decision was not made due to any disagreements with Deloitte.

     

    (a)Dismissal of independent registered public accounting firm

     

    Deloitte has served as the Company’s independent registered public accounting firm since 2018.

     

    The audit reports of Deloitte on the consolidated financial statements of the Company as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, and on the Company's internal control over financial reporting as of December 31, 2023 and 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”), did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

     

    During the years ended December 31, 2022 and 2023, and in the subsequent interim period preceding the expiry of Deloitte's engagement as the Company’s independent registered public accounting firm, there has been no disagreement (as defined in Item 16F(a)(1)(iv) of the instruction to Form 20-F and the related instructions thereto) with the Company on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Deloitte, would have caused them to make reference to the subject matter of the disagreements in their reports on the consolidated financial statements of the Company for such fiscal years, and no “reportable events” occurred (as set forth in Item 16F(a)(1)(v) of the instruction to Form 20-F).

     

    The Company has provided Deloitte with a copy of the above disclosure and requested that Deloitte furnish the Company with a letter addressed to the SEC stating whether or not it agrees with the above statements. A copy of Deloitte’s letter is furnished as Exhibit 16.1 to this Form 6-K.

     

    (b)Engagement of new independent registered public accounting firm

     

    Grant Thornton is engaged to audit and report on the consolidated financial statements of the Company as of and for the year ending December 31, 2024. Grant Thornton will also audit the Company’s internal control over financial reporting as of December 31, 2024.

     

     

     

    EXHIBIT INDEX

     

    Exhibit No. 

    Description 

    16.1 Letter of Deloitte Touche Tohmatsu Certified Public Accountants LLP, dated July 19, 2024, addressed to the U.S. Securities and Exchange Commission

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      111, INC.
       
    Date:  July 19, 2024 By: /s/ Junling Liu
        Name: Junling Liu
        Title: Chief Executive Officer

     

    Get the next $YI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $YI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    111, Inc. Announces Third Quarter 2025 Unaudited Financial Results

    Transition from An Asset-Heavy Business Model to An Asset-Light Business ModelAchieved Quarterly Non-GAAP Net ProfitabilityMaintained Non-GAAP Operational Profitability for Three Consecutive QuartersAchieved Quarterly Positive Operating Cash FlowSHANGHAI, Dec. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Total operating expenses were RMB180.3 million (US$25.3 million)

    12/17/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Second Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 20 Basis Points YoYMaintained Positive Operating Cash Flow in the First Half of the YearSHANGHAI, Sept. 17, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Total operating expenses were RMB185.3 million (US$25.9 million), an improvement of 9.3% compared to RMB204.3 million in

    9/17/25 2:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces First Quarter 2025 Unaudited Financial Results

    Maintained Quarterly Operational ProfitabilityOperating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoYMaintained Quarterly Positive Operating Cash FlowSHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Net revenues were RMB3.5 billion (US$486.3 million), remaining relatively flat compared to the same quarter last year.Total operating expenses

    6/19/25 3:03:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    SEC Filings

    View All

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    12/17/25 6:13:16 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by 111 Inc.

    6-K - 111, Inc. (0001738906) (Filer)

    9/17/25 6:09:10 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form 20-F/A filed by 111 Inc.

    20-F/A - 111, Inc. (0001738906) (Filer)

    8/29/25 6:03:53 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on 111, Inc. with a new price target

    Citigroup resumed coverage of 111, Inc. with a rating of Buy and set a new price target of $16.00

    4/15/21 6:56:01 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Leadership Updates

    Live Leadership Updates

    View All

    111, Inc. Announces Change to Board of Directors

    SHANGHAI, Nov. 4, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that Dr. Leon Lian Yong Chen has tendered his resignation from the position as the Company's director for personal reasons, effective on November 4, 2024. The board has also appointed Mr. Yang "Luke" Chen, currently serving as the Company's Senior Finance Executive, as a new director, effective November 4, 2024. Dr. Lian Yong Chen has served on the board of directors of the Company since May 2019. "I am grateful to Dr

    11/4/24 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 Announces Appointment of New Auditor

    SHANGHAI, July 19, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced  the appointment of  Grant Thornton Zhitong Certified Public Accountants LLP ("Grant Thornton") as the Company's independent registered public accounting firm, effective July 19, 2024, replacing Deloitte Touche Tohmatsu Certified Public Accountants LLP. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by 111's boar

    7/19/24 8:45:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

    SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, established by the Company's Board of Directors (the "Board") has retained Houlihan Lokey China Limited as its independent financial advisor and Kirkland & Ellis as its U.S. legal counsel in connection with its review and evaluation of the previously announced preliminary non-binding proposal letter dated September 9, 2022 (the "Proposal")

    9/23/22 12:30:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Financials

    Live finance-specific insights

    View All

    111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    Achieved First-Ever Annual Operating ProfitBottom Line Improved by RMB332.7 Million YoY in 2024Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoYAchieved First-Ever Annual Positive Operating Cash FlowSHANGHAI, March 20, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Four

    3/20/25 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow

    SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- 111, Inc. (NASDAQ:YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2024 ended December 31, 2024, before the U.S. market opens on Thursday, March 20, 2025. 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, March 20, 2025 (7:30 PM Beijing Time on the same day). Details for the conference call are as follows: Conference Topic: 111, Inc. Fourth Q

    2/20/25 5:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

    Maintained Operational Profitability for the Third Consecutive QuarterOperating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoYHeld Positive Operating Cash Flow for Three Consecutive QuartersSHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ:YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Net revenues were RMB3.6 billion (US$513.1 million), remaining relatively flat compared to the same

    11/27/24 1:00:00 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $YI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    2/27/24 8:02:40 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    7/17/23 9:00:05 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13D/A filed by 111 Inc. (Amendment)

    SC 13D/A - 111, Inc. (0001738906) (Subject)

    10/31/22 7:57:04 AM ET
    $YI
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples